Table 4.

Antigenic linear B-cell epitopes of lipoprotein Q75FL0 with their conservancy and allergenicity.

No.	Start position	End position	Peptide	Peptide Length	Allergenicity	Conservany (%)
1	5	16	YSSSFILIIKKG	12	No	2.17
2	20	40	MKKILILLIALSFAVFGCSHK	21	Yes	30.43
3	42	54	KGILLPFLTLLNQ	13	Yes	60.87
4	76	82	GSVVIVD	7	No	76.09
5	91	96	SGVLLP	6	No	41.30
6	301	321	GSIPFTYNTVQTIPLNLVVTD	21	No	54.35
7	329	335	GATVIVS	7	No	93.48
8	340	345	HILFQG	6	No	89.13
9	359	371	VETALGQITLEIT	13	No	65.22
10	377	390	ISNVINLINVVGIN	14	No	54.35
11	394	406	KYEVLLPVAAVPT	13	No	17.39
12	427	432	SSLIRI	6	No	71.74
13	434	449	AEGVSTVAYEDLYPSA	16	No	73.91
14	455	462	NDYVLHIH	8	No	97.83
15	470	477	AGDVIRLR	8	No	97.83
16	479	486	TYQHVARG	8	No	91.30
17	490	504	KHTFFLKLPVAVGAT	15	No	60.87
18	506	512	SRKVVRE	7	No	84.78
19	522	529	TKTVSSSD	8	No	63.04
20	551	570	PGGVYKPGYIATIEIVFNSP	20	No	56.52
21	576	588	LGSYPYDIFIKVI	13	No	60.87
22	594	600	IHFPGLY	7	No	100.00
23	617	624	WAILVPGA	8	No	95.65
24	666	674	QAKVFPVPD	9	No	95.65
25	680	686	MGFLLRS	7	No	58.70
26	691	712	AILIAILLIGAGAAVAYILKRR	22	No	56.52

26 antigenic sites were predicted. Residues underlined and in bold were also predicted as conformational B-cell and CTL epitopes respectively.